Economic evaluation of antidepressive agents: A systematic critique of experimental and observational studies

Journal of Clinical Psychopharmacology

Volumn 23, Issue 2, 2003, Pages 145-154

  Barbui, Corrado ^a,d   Percudani, Mauro ^b   Hotopf, Matthew ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b Hospital of Legnano   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; DEPRESSION; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DEPRESSIVE DISORDER; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037382162     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200304000-00007     Document Type: Article

References (53)

1. Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care. Fam Practice 1999;16:103-11.
2. Barbui C, Campomori A, Mezzalira L, et al. Psychotropic drug use in Italy 1984-1999: impact of regulatory changes. Int Clin Psychopharmacol 2001;16:227-33.
3. Hotopf MH, Lewis G, Normand C. Are SSRI a cost effective alternative to tricyclics? Br J Psychiatry 1996;168:404-409.
4. Schulberg HC, Katon W, Simon G, et al. Treating major depression in primary care practice. An update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55:1121-7.
5. Crismond ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999;60:142-56.
6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(suppl 4):1S-45S
7. Canadian Psychiatric Association. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46(suppl 1):38S-58S.
8. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-14.
9. Geisler E, Heller O, eds. Managing Technology in Healthcare. Norwell, MA: Kluwer Academic, 1996.
10. Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001;322:1596-8.
11. Berndt ER, Russell JM, Miceli R, et al. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Value Health 2000;3:208-21.
12. Beuzen JN, Ravily VF, Souetre EJ, et al. Impact of fluoxetine on work loss in depression. Int Clin Psychopharmacol 1993;8:319-21.
13. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary care setting in France. Pharmacoeconomics 1998;13:157-69.
14. Claxton AJ, Chawla AJ, Kennedy S. Absenteeism among employees treated for depression. J Occup Environ Med 1999;41:605-11.
15. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997;48:1420-6.
16. Croghan TW, Obenchain RL, Crown WE. What does treatment of depression really cost? Health Affairs 1998a;17:198-208.
17. Croghan TW, Melfi CA, Crown WE, et al. Cost-effectiveness of antidepressant medications. J Ment Health Policy Econ 1998b; 1:109-17.
18. Croghan TW, Kniesner TJ, Melfi CA, et al. Effect of antidepressant choice on the incidence and economic intensity of hospitalisation among depressed individuals. Adm Policy Ment Health 2000;27: 183-95.
19. Crown WH, Hylan TR, Meneades L. Antidepressant selection and use and healthcare expenditures. An empirical approach. Pharmacoeconomics 1998;13:435-48.
20. Crown WH, Treglia M, Meneades L, et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001;4:295-307.
21. D'Mello DA, Finkbeiner DS, Kocher KN. The cost of antidepressant overdose. Gen Hosp Psychiatry 1995;17:454-55.
22. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97-111.
23. Griffiths RI, Sullivan EM, Frank RG, et al. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy following selective serotonin reuptake inhibitor therapy for depression. Pharmacoeconomics 1999;15:495-505.
24. Hosak L, Tuma I, Hanus H, et al. Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. Acta Medica (Hradec Kralove) 2000;43:133-7.
25. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998;47:71-9.
26. Kapur N, House A, Creed F, et al. Cost of antidepressant overdose: a preliminary study. Br J Gen Practice 1999;49:733-4.
27. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999;2:269-80.
28. Melton ST, Kirkwood CK, Farrar TW, et al. Economic evaluation of paroxetine and imipramine in depressed outpatients. Psychopharmacol Bull 1997;33:93-100.
29. Nurnberg HG, Hensley PL, Thompson PM, et al. Modelling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv 1999;50:1351-3.
30. Ozminkowski RJ, Hylan TR, Melfi CA, et al. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolised by the cytochrome P-450 system. Clin Ther 1998; 20:780-96.
31. Ramchandani P, Murray B, Hawton K, et al. Deliberate self poisoning with antidepressant drugs: a comparison of the relative hospital costs of cases of overdose of tricyclic with those of selective-serotonin re-uptake inhibitors. J Affect Disord 2000;60:97-100.
32. Revicki DA, Palmer CS, Phillips SD, et al. Acute medical costs of fluoxetine versus tricyclic antidepressants. A prospective multicentre study of antidepressant drug overdoses. Pharmacoeconomics 1997; 11:48-55.
33. Sacristan JA, Gilaberte I, Hylan TR, et al. Costes del tratamiento con nuevos antidepresivos en la pratica clinica. Atencion Primaria 1999;23:15-16.
34. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organisation. Clin Ther 1994;16:715-29.
35. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organisation. J Int Med Res 1995; 23:395-412.
36. Sclar DA, Skaer TL, Robison LM, et al. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. J Clin Psychiatry 1998;59(suppl 2):13-17.
37. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999;19(suppl 1):47S-54S.
38. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998;13:61-70.
39. Simon GE, Heiligenstein JH, Revicki DA, et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomised trial. Arch Fam Med 1999;8:319-25.
40. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Research 1995; 56:556-67.
41. Skaer TL, Sclar DA, Robison LM, et al. Antidepressant pharmacotherapy: effect on women's resource utilisation within a health maintenaince organisation. J Appl Ther 1996;1:45-52.
42. Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO. Med Interface 1996;9:88-92.
43. Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdose and resultant emergency department services: the impact of SSPIs. Psychopharmacol Bull 1997;33:667-70.
44. Sullivan EM, Griffiths RI, Frank RG, et al. One-year costs of second-line therapies for depression. J Clin Psychiatry 2000;61:290-8.
45. Tarricone R, Fattore G, Gerzeli S, et al. The costs of pharmacological treatment for major depression. The Italian Prospective Multicentre Observational Incidence-Based study. Pharmacoeconomics 2000;17:167-74.
46. Tollefson GD, Souetre E, Thomander L, et al. Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes. Int Clin Psychopharmacol 1993;8:281-93.
47. Treglia M, Neslusan C, Dunn RL. Fluoxetine and dothiepin therapy in primary care and health resource utilisation:evidence from the United Kingdom. IntJ Psychiatry Clin Practice 1999;3:23-30.
48. Viale GL. An economic analysis of physicians' prescribing of selective serotonin reuptake inhibitors. Hospital Pharmacy 1998; 33:847-50.
49. Altamura AC, Percudani M. The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. J Clin Psychiatry 1993;54(suppl):29-37.
50. Barbui C, Hotopf M. Amitriptyline versus the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129-44.
51. Percudani M, Belloni G, Contini A, et al. Monitoring community psychiatric services in Italy: differences between patients who leave care and those who stay in treatment. Br J Psychiatry 2002; 180:254-9.
52. Stahl MMS, Lindquist M, Petterson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53:163-9.
53. Black N. High quality clinical databases: breaking down barriers. Lancet 1999;353:1205-6.